75 results
8-K
INM
InMed Pharmaceuticals Inc
20 Mar 24
InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance
1:44pm
Qualifications Department of Nasdaq that the Company has been granted an additional 180-day compliance period, or until September 16, 2024
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
20 Mar 24
InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance
1:44pm
cannabinoid analogs, today announced that it has received a notification letter from the Listing Qualifications Department of Nasdaq Stock Market LLC (“Nasdaq
8-K
EX-99.1
INM
InMed Pharmaceuticals Inc
29 Nov 23
Regulation FD Disclosure
2:50pm
. Mauro Maccarrone
Dr. Mauro Maccarrone is an international expert in cannabinoid research working with the Department of Biotechnological and Applied
8-K
EX-10.1
ddgwv590
27 Oct 23
Entry into a Material Definitive Agreement
7:16pm
DEFA14A
ui9opg7 s4egqef346d
27 Oct 23
Additional proxy soliciting materials
4:08pm
8-K
lukw ejs9x0u4w1q86
22 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7:29pm
8-K
EX-99.1
yo9 37x3kap54jg3cu
13 Dec 22
InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor
4:01pm
8-K
1bdmuc orkp75v3liw3
13 Dec 22
InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor
4:01pm
8-K
EX-99.1
n3fr xb9xch5n0a97b
13 Dec 22
InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor
3:47pm
8-K
EX-10.1
y48ej5x04xw241u 2m7
21 Nov 22
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
7:02pm
8-K
EX-99.1
hyr6ah dg9fy
23 Sep 22
InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update
4:53pm
8-K
EX-10.1
pckg0u
13 Sep 22
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
9:59pm
8-K
EX-10.1
daweqlaqdivj
19 Jul 22
InMed Announces Appointment of Chief Operating Officer
7:43pm